Solid Biosciences (SLDB) CTO earns 54,925 RSUs on performance milestone

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Solid Biosciences Inc. reported that Chief Technology Officer Paul Herzich acquired 54,925 restricted stock units (RSUs) linked to the company’s common stock as part of his equity compensation. These RSUs were earned under performance stock units (PSUs) originally granted on June 11, 2024.

The PSUs vest in four equal 25% tranches upon achieving independent, pre-set performance milestones tied to business objectives. The Board determined the second milestone was met on January 29, 2026, triggering this 54,925-unit award. These shares will actually vest only if Herzich remains in service on the related Evaluation Date, anticipated in the first quarter of 2027.

Insider Trade Summary 10b5-1

1 transaction reported

Mixed 1 txn

Insider Herzich Paul

Role Chief Technology Officer

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	54,925	$0.00	--

Holdings After Transaction: Restricted Stock Units — 54,925 shares (Direct, null)

Footnotes (1)

Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs"). Performance stock units ("PSUs") were granted on June 11, 2024, and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the second Performance Milestone was determined by the Board to be met on January 29, 2026, and the shares related to such Performance Milestone will vest subject to the grantee's continued service with the Company on the Evaluation Date, which is anticipated to occur in the first quarter of 2027.

Key Figures

RSUs granted: 54,925 units Shares following transaction: 54,925 units Grant date of PSUs: June 11, 2024 +3 more

6 metrics

RSUs granted 54,925 units Restricted stock units tied to common stock from PSU award

Shares following transaction 54,925 units Total RSUs reported as held after this grant

Grant date of PSUs June 11, 2024 Original performance stock unit grant date

Milestone certification date January 29, 2026 Second performance milestone determined achieved by Board

Vesting structure 25% per milestone Four independent performance milestones under PSU award

Expected vesting window Q1 2027 Anticipated Evaluation Date for vesting of related RSUs

Key Terms

Restricted Stock Units, Performance stock units, Performance Milestones, non-market and non-financial, +1 more

5 terms

Restricted Stock Units financial

"Each restricted stock unit represents a contingent right to receive one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Performance stock units financial

"Performance stock units ("PSUs") were granted on June 11, 2024"

Performance stock units are a type of company award that grants employees shares of stock only if certain performance goals are met. They motivate employees to work toward specific company achievements, aligning their interests with those of shareholders. For investors, they can influence a company's future stock supply and reflect management’s confidence in reaching key targets.

Performance Milestones financial

"four independent performance milestones predetermined by the Board ("Performance Milestones")"

non-market and non-financial financial

"The Performance Milestones are tied to business objectives and are non-market and non-financial in nature"

Evaluation Date financial

"subject to continued service on the Evaluation Date, anticipated in the first quarter of 2027"

Form 4 Insider Transactions: What Each Field Means →

04/21/2026 - 04:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Herzich Paul

(Last)

(First)

(Middle)

C/O SOLID BIOSCIENCES INC.

500 RUTHERFORD AVENUE, THIRD FLOOR

(Street)

CHARLESTOWN

MASSACHUSETTS

02129

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Solid Biosciences Inc. [ SLDB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Technology Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
01/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	01/29/2026		A		54,925		⁽²⁾	⁽²⁾	Common Stock	54,925	$0.00	54,925	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").

2. Performance stock units ("PSUs") were granted on June 11, 2024, and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the second Performance Milestone was determined by the Board to be met on January 29, 2026, and the shares related to such Performance Milestone will vest subject to the grantee's continued service with the Company on the Evaluation Date, which is anticipated to occur in the first quarter of 2027.

	/s/ Kimberly Cornwell as attorney-in-fact for Paul Herzich	04/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Solid Biosciences (SLDB) report for Paul Herzich?

Solid Biosciences reported Chief Technology Officer Paul Herzich receiving 54,925 restricted stock units. These RSUs come from previously granted performance stock units that vested when a non-financial performance milestone was certified as achieved by the Board on January 29, 2026, subject to future service.

How many RSUs did the SLDB CTO acquire in this Form 4 filing?

The CTO acquired 54,925 restricted stock units tied to Solid Biosciences common stock. Each RSU represents the right to receive one share, contingent on continued service through a specified Evaluation Date expected in the first quarter of 2027 under the performance award terms.

What are the terms of the performance stock units mentioned for Solid Biosciences (SLDB)?

The performance stock units were granted on June 11, 2024 and are linked to four independent performance milestones. Each milestone triggers vesting of 25% of the target RSUs when the Board certifies achievement of specific non-market, non-financial business objectives on designated evaluation dates.

Why did 54,925 RSUs become earned for the SLDB CTO on January 29, 2026?

The Board determined that the second performance milestone under the June 11, 2024 PSU grant had been met on January 29, 2026. That certification caused 25% of the target RSUs, equal to 54,925 units, to be awarded, subject to the CTO’s continued service through the Evaluation Date.

When will the newly awarded RSUs for Solid Biosciences’ CTO actually vest?

The RSUs related to the second performance milestone will vest only if the grantee continues service through the Evaluation Date. That Evaluation Date is anticipated to occur in the first quarter of 2027, according to the performance award’s terms and the Board’s certification language.

Are the SLDB performance milestones based on stock price or financial metrics?

No, the performance milestones are described as non-market and non-financial in nature. They are tied to the achievement of certain business objectives that the Board certifies on specified evaluation dates, rather than to stock price movements or traditional financial performance measures like revenue or earnings.